What the FDA labels say about taking them together
Dipyridamole and heparin
Heparin's FDA label (Heparin Sodium) of April 30, 2026 names dipyridamole in its drug interactions section; the dipyridamole label PlainMeds reads does not name heparin. The heparin label: “Drugs such as NSAIDS, dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIv/IIa antagonists, and others that interfere with platelet-aggregation reactions may induce bleeding and …”
Check it at the source: the dipyridamole FDA label on DailyMed (effective September 16, 2023, Zydus Pharmaceuticals USA Inc.); the heparin FDA label on DailyMed (effective November 28, 2025, Fresenius Kabi USA, LLC).
What does the dipyridamole label say about heparin?
Dipyridamole's label (effective September 16, 2023) does not name heparin in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Dipyridamole), Zydus Pharmaceuticals USA Inc., effective September 16, 2023 (SPL set 004bada0-dbf7-4a94-8792-6833d7eeda2b), via openFDA; the full label on DailyMed
What does the heparin label say about dipyridamole?
Heparin Sodium label (Fresenius Kabi USA, LLC, April 30, 2026), drug interactionsDrugs such as NSAIDS (including salicylic acid, ibuprofen, indomethacin, and celecoxib), dextran, phenylbutazone, thienopyridines, dipyridamole, hydroxychloroquine, glycoprotein IIb/IIIa antagonists (including abciximab, eptifibatide, and tirofiban), and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Heparin Sodium label (Hospira, Inc., May 12, 2026), drug interactionsDrugs such as acetylsalicylic acid, dextran, phenylbutazone, ibuprofen, indomethacin, dipyridamole, hydroxychloroquine and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving heparin sodium.
Source: FDA drug label (Heparin Sodium, NDA017029), Fresenius Kabi USA, LLC, effective April 30, 2026 (SPL set 2a173253-dfdc-4d9d-8dee-b9c13e6fa9f5), via openFDA
Source: FDA drug label (Heparin Sodium, NDA018916), Hospira, Inc., effective May 12, 2026 (SPL set 0413f511-6b34-4c15-e48b-3fad08baacbe), via openFDA
Source: FDA drug label (Heparin Sodium In Sodium Chloride, NDA018609), Baxter Healthcare Corporation, effective January 3, 2022 (SPL set 0d929726-76c3-48fc-b4e7-fd06409f9fb3), via openFDA
Source: FDA drug label (Heparin Sodium), Fresenius Kabi USA, LLC, effective November 28, 2025 (SPL set d55b4a63-0c04-4874-b74f-9e9b9e8b008c), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dipyridamole | Heparin | |
|---|---|---|
| Labeled for | n/a | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.236 per tablet 75 mg tablet | $1.18 per mL 5,000 unit/mL vial |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once